Scientists reprogram brain cells to remove Alzheimer’s plaques with a single injection, showing a new approach to long-term ...
A widely publicised Cochrane review published on April 16, 2026, set out to synthesise evidence on the efficacy and safety of amyloid β-targeting monoclonal antibodies for Alzheimer's disease.1 The ...
Plasma pTau217 may detect initial buildup of AD-related brain changes before they can be detected by current ‘gold standard’ ...
Drugs that target amyloid beta proteins in the brain likely have no clinically meaningful positive effects, while increasing ...
IFLScience on MSN
Alzheimer’s drugs that target amyloid plaques have no meaningful effects, says major review, sparking fierce debate from scientists
Alzheimer’s disease drugs that target amyloid-β, one of the problematic proteins associated with the disease, may have “no ...
Scientists at Washington University in St. Louis have engineered brain cells to hunt and destroy amyloid plaques, cutting toxic buildup by roughly half in aged mice with advanced Alzheimer’s-like ...
Study highlights how compensatory inhibitory signaling contributes to cognitive decline in Alzheimer’s disease. They found ...
Top drugmakers have spent more than a decade investigating and advancing anti-amyloid Alzheimer's medicines in clinical ...
Drugs designed to treat Alzheimer's disease by targeting amyloid proteins was seen in high amounts in patients' brains, but ...
Rates of amyloid build-up in the brain accelerate and then decelerate before reaching a plateau, providing a possible 15-year window of opportunity for intervention to prevent Alzheimer's disease (AD) ...
Evidence of iatrogenic beta-amyloid transmission was identified in two patients who developed early-onset cerebral amyloid angiopathy decades after undergoing pediatric cardiac surgery. The findings ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results